Roche: Alzheimer's disease trial results
(CercleFinance.com) - Roche, in collaboration with the Banner Alzheimer's Institute, today announced results from the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial in Colombia.
The study evaluated the potential of the investigational drug crenezumab to slow or prevent Alzheimer's disease in cognitively intact people who carry a specific genetic mutation that causes early-onset Alzheimer's disease.
The trial failed to demonstrate a statistically significant clinical benefit in any of its primary endpoints assessing the rate of change in cognitive ability or episodic memory function, as measured by the API ADAD Cognitive Composite Score and the Selective Free Recall Test (FCS RT) Tracking Index, respectively.
Roche has been working in collaboration with the Banner Alzheimer's Institute, the University of Antioquia in Colombia and the National Institute of Aging on this pioneering prevention study for over a decade.
Related sources were naturally disappointed that the treatment did not demonstrate a statistically significant clinical benefit.
Copyright (c) 2022 CercleFinance.com. All rights reserved.